Imetelstat Reduces Clonal Burden in Lower-Risk MDS Beyond Symptom Relief
Phase 3 IMerge data show imetelstat cuts mutation burden and may modify myelodysplastic neoplasm biology in transfusion-dependent patients.
Summary
In the Phase 3 IMerge trial, imetelstat—a first-in-class telomerase inhibitor—demonstrated significant reductions in variant allele frequency (VAF) across multiple MDS-associated mutations compared to placebo in lower-risk myelodysplastic neoplasm patients. Patients achieving sustained ≥1-year red blood cell transfusion independence showed corresponding reductions in SF3B1, TET2, DNMT3A, and ASXL1 mutation burden, cytogenetic clone normalization, and bone marrow ring sideroblast reduction. Sixty percent of long-term responders also showed ≥50% reduction in telomerase activity. These findings suggest imetelstat acts beyond symptomatic relief, potentially targeting clonal hematopoietic stem and progenitor cells and modifying underlying disease biology.
Detailed Summary
Lower-risk myelodysplastic neoplasms (LR-MDS) are hematopoietic stem cell cancers characterized by clonal mutations, ineffective hematopoiesis, and chronic anemia requiring regular red blood cell (RBC) transfusions. Until recently, available therapies—including erythropoiesis-stimulating agents (ESAs) and luspatercept—focused exclusively on symptomatic relief without meaningfully targeting the underlying clonal disease. Imetelstat, a first-in-class direct telomerase inhibitor, offers a mechanistically distinct approach by targeting telomerase activity in neoplastic stem and progenitor cells.
This exploratory analysis draws from the randomized, double-blind, placebo-controlled Phase 3 IMerge study (NCT02598661), which enrolled transfusion-dependent LR-MDS patients without del(5q) who were relapsed, refractory, or ineligible for ESAs. Patients received imetelstat 7.5 mg/kg IV every 4 weeks. Next-generation sequencing (NGS) of 36 MDS-associated genes was performed on peripheral blood at baseline and every 12 weeks, with VAF changes tracked over time. Cytogenetic response was assessed by independent review using bone marrow karyotyping, bone marrow ring sideroblasts (RS) were counted manually, and telomerase activity (TA) and hTERT RNA levels were also evaluated. For four illustrative cases, multiparametric flow cytometry assessed erythroid maturation dynamics.
Key results were striking. Patients treated with imetelstat exhibited sustained VAF reductions across multiple mutations compared to placebo. Critically, 70% of patients achieving a cytogenetic response with imetelstat also achieved ≥1-year RBC transfusion independence (TI). Patients with ≥50% maximum VAF reduction in SF3B1 achieved ≥1-year RBC-TI at a rate of 58% vs. 7% for those without; TET2 reductions yielded 90% vs. 9%; DNMT3A reductions yielded 100% vs. 13%; and ASXL1 reductions yielded 50% vs. 0%. Patients with ≥50% reduction in bone marrow RS achieved ≥1-year RBC-TI at 46% vs. 0%. Additionally, 60% of ≥1-year RBC-TI responders had ≥50% reductions in TA/hTERT RNA, consistent with on-target telomerase inhibition in clonal progenitors.
These findings carry significant implications for the treatment paradigm of LR-MDS. They suggest imetelstat may act as a disease-modifying agent—not merely alleviating transfusion burden, but actively suppressing the malignant clone. The correlation between molecular responses (VAF reduction, cytogenetic normalization) and durable clinical responses (≥1-year RBC-TI) supports the concept that deeper biological responses drive sustained remission. This positions imetelstat as qualitatively different from prior LR-MDS therapies.
Important caveats apply. These are exploratory, hypothesis-generating analyses from a Phase 3 trial not primarily powered for molecular endpoints. Sample sizes for subgroup analyses are small. The flow cytometry data derive from only four illustrative cases. Causality between molecular and clinical responses requires further prospective validation.
Key Findings
- 70% of cytogenetic responders to imetelstat achieved ≥1-year RBC transfusion independence.
- ≥50% VAF reduction in TET2 was associated with 90% vs. 9% rate of ≥1-year RBC-TI.
- ≥50% bone marrow ring sideroblast reduction correlated with 46% vs. 0% ≥1-year RBC-TI rate.
- 60% of ≥1-year RBC-TI responders had ≥50% reduction in telomerase activity/hTERT RNA.
- Imetelstat reduced clonal mutation burden across SF3B1, TET2, DNMT3A, and ASXL1 versus placebo.
Methodology
Phase 3 randomized, double-blind, placebo-controlled IMerge trial (NCT02598661) in transfusion-dependent LR-MDS patients. NGS of 36 MDS-associated genes on peripheral blood samples at baseline and every 12 weeks; cytogenetic response by independent review; bone marrow ring sideroblasts counted manually; telomerase activity and hTERT RNA assessed; four illustrative cases underwent multiparametric flow cytometry.
Study Limitations
Molecular endpoint analyses are exploratory and the trial was not powered to detect differences in VAF or cytogenetic outcomes. Subgroup sample sizes are small, limiting statistical robustness. Flow cytometry erythroid maturation data derive from only four illustrative patients at a single center.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.